Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

被引：23
|
作者：
Verma, Dushyant [1 ]
Kantarjian, Hagop [1 ]
Jain, Nitin [1 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 07期
关键词：
D O I：
10.1080/10428190802043903
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1399 / 1402
页数：4
相关论文
共 50 条
  • [21] How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
    Ross, David M.
    Hughes, Timothy P.
    LEUKEMIA & LYMPHOMA, 2008, 49 (07) : 1230 - 1231
  • [22] Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
    Colombat, M
    Fort, MP
    Chollet, C
    Marit, G
    Roche, C
    Preudhomme, C
    Reiffers, J
    Praloran, V
    Mahon, FX
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 162 - 168
  • [23] Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR)
    Campiotti, L.
    Ferrari, M.
    Orlandi, E. M.
    Suter, M. B.
    Squizzato, A.
    Guasti, L.
    Marino, F.
    Cosentino, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
  • [24] Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience
    Saleem, Umera
    Hafeez, Talha
    Raza, Syed Ali
    Tahir, Muhammad
    Khalid, Fatima
    Islam, Muhammad Khurrum
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (04)
  • [25] Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response
    Steegmann, JL
    Requena, MJ
    García-Buey, ML
    Granados, E
    Romero, R
    Fernández-Rañada, JM
    Moreno, R
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 59 (01) : 95 - 97
  • [26] Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
    Francisco Cervantes
    Juan-Gonzalo Correa
    Isabel Pérez
    Valentín García-Gutiérrez
    Sara Redondo
    Dolors Colomer
    Antonio Jiménez-Velasco
    Juan-Luis Steegmann
    Fermín Sánchez-Guijo
    Francisca Ferrer-Marín
    Arturo Pereira
    Santiago Osorio
    Annals of Hematology, 2017, 96 : 81 - 85
  • [27] Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
    Katagiri, Seiichiro
    Mizoguchi, Izuru
    Yoshimoto, Takayuki
    Mizuguchi, Junichiro
    Ohyashiki, Junko H.
    Ohyashiki, Kazuma
    BLOOD, 2012, 120 (21)
  • [28] Imatinib Dose Reduction in Patients with Chronic Myeloid Leukemia in Sustained Deep Molecular Response
    Correa, Juan
    Cervantes, Francisco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S228 - S228
  • [29] Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
    Cervantes, Francisco
    Correa, Juan-Gonzalo
    Perez, Isabel
    Garcia-Gutierrez, Valentin
    Redondo, Sara
    Colomer, Dolors
    Jimenez-Velasco, Antonio
    Steegmann, Juan-Luis
    Sanchez-Guijo, Fermin
    Ferrer-Marin, Francisca
    Pereira, Arturo
    Osorio, Santiago
    ANNALS OF HEMATOLOGY, 2017, 96 (01) : 81 - 85
  • [30] Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia
    Hill, Brittany G.
    Shen, Ann Qi
    El Rassi, Fuad
    Khoury, Hanna Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : E68 - E69
12345